Literature DB >> 15826180

Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases.

Yu Chen1, Brian Shoichet, Richard Bonnet.   

Abstract

CTX-M enzymes are an emerging group of extended spectrum beta-lactamases (ESBLs) that hydrolyze not only the penicillins but also the first-, second-, and third-generation cephalosporins. Although they have become the most frequently observed ESBLs in certain areas, there are few effective inhibitors and relatively little is known about their detailed mechanism. Here we describe the X-ray crystal structures of CTX-M enzymes in complex with different transition-state analogues and beta-lactam inhibitors, representing the enzyme as it progresses from its acylation transition state to its acyl enzyme complex to the deacylation transition state. As the enzyme moves along this reaction coordinate, two key catalytic residues, Lys73 and Glu166, change conformations, tracking the state of the reaction. Unexpectedly, the acyl enzyme complex with the beta-lactam inhibitor cefoxitin still has the catalytic water bound; this water had been predicted to be displaced by the unusual 7alpha-methoxy of the inhibitor. Instead, the 7alpha-group appears to inhibit by preventing the formation of the deacylation transition state through steric hindrance. From an inhibitor design standpoint, we note that the best of the reversible inhibitors, a ceftazidime-like boronic acid compound, binds to CTX-M-16 with a K(i) value of 4 nM. When used together in cell culture, this inhibitor reversed cefotaxime resistance in CTX-M-producing bacteria. The structure of its complex with CTX-M enzyme and the structural view of the reaction coordinate described here provide templates for inhibitor design and intervention to combat this family of antibiotic resistance enzymes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826180      PMCID: PMC1360657          DOI: 10.1021/ja042850a

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  41 in total

Review 1.  Expanding the model: anisotropic displacement parameters in protein structure refinement.

Authors:  E A Merritt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-06

2.  Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs.

Authors:  Xiaojun Wang; George Minasov; Brian K Shoichet
Journal:  J Mol Biol       Date:  2002-06-28       Impact factor: 5.469

3.  Evidence for an oxyanion hole in serine beta-lactamases and DD-peptidases.

Authors:  B P Murphy; R F Pratt
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

4.  Crystal structures of the Bacillus licheniformis BS3 class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin.

Authors:  Eveline Fonzé; Marc Vanhove; Georges Dive; Eric Sauvage; Jean-Marie Frère; Paulette Charlier
Journal:  Biochemistry       Date:  2002-02-12       Impact factor: 3.162

5.  Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme.

Authors:  Michiyoshi Nukaga; Kayoko Mayama; Andrea M Hujer; Robert A Bonomo; James R Knox
Journal:  J Mol Biol       Date:  2003-04-18       Impact factor: 5.469

6.  Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin.

Authors:  Tatsuro Shimamura; Akiko Ibuka; Shinya Fushinobu; Takayoshi Wakagi; Masaji Ishiguro; Yoshikazu Ishii; Hiroshi Matsuzawa
Journal:  J Biol Chem       Date:  2002-09-08       Impact factor: 5.157

7.  Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a beta-lactamase transition-state analog.

Authors:  E Lobkovsky; E M Billings; P C Moews; J Rahil; R F Pratt; J R Knox
Journal:  Biochemistry       Date:  1994-06-07       Impact factor: 3.162

8.  Thermodynamic evaluation of a covalently bonded transition state analogue inhibitor: inhibition of beta-lactamases by phosphonates.

Authors:  Rajesh Nagarajan; R F Pratt
Journal:  Biochemistry       Date:  2004-08-03       Impact factor: 3.162

9.  Crystal structure of the E166A mutant of extended-spectrum beta-lactamase Toho-1 at 1.8 A resolution.

Authors:  A Ibuka; A Taguchi; M Ishiguro; S Fushinobu; Y Ishii; S Kamitori; K Okuyama; K Yamaguchi; M Konno; H Matsuzawa
Journal:  J Mol Biol       Date:  1999-02-05       Impact factor: 5.469

10.  Nanomolar inhibitors of AmpC beta-lactamase.

Authors:  Federica Morandi; Emilia Caselli; Stefania Morandi; Pamela J Focia; Jesús Blázquez; Brian K Shoichet; Fabio Prati
Journal:  J Am Chem Soc       Date:  2003-01-22       Impact factor: 15.419

View more
  54 in total

1.  Noncovalent complexes of an inactive mutant of CTX-M-9 with the substrate piperacillin and the corresponding product.

Authors:  David Leyssene; Julien Delmas; Frédéric Robin; Antony Cougnoux; Lucie Gibold; Richard Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Crystal structures of covalent complexes of β-lactam antibiotics with Escherichia coli penicillin-binding protein 5: toward an understanding of antibiotic specificity.

Authors:  George Nicola; Joshua Tomberg; R F Pratt; Robert A Nicholas; Christopher Davies
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

3.  Unexpected enzyme TEM-126: role of mutation Asp179Glu.

Authors:  J Delmas; F Robin; F Bittar; C Chanal; R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9.

Authors:  J Delmas; F Robin; F Carvalho; C Mongaret; R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  The acylation mechanism of CTX-M beta-lactamase at 0.88 a resolution.

Authors:  Yu Chen; Richard Bonnet; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2007-04-05       Impact factor: 15.419

6.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 7.  Resistance to antibiotics targeted to the bacterial cell wall.

Authors:  I Nikolaidis; S Favini-Stabile; A Dessen
Journal:  Protein Sci       Date:  2014-01-17       Impact factor: 6.725

8.  Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.

Authors:  Wei Ke; Jared M Sampson; Claudia Ori; Fabio Prati; Sarah M Drawz; Christopher R Bethel; Robert A Bonomo; Focco van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

9.  Kinetic characterization of GES-22 β-lactamase harboring the M169L clinical mutation.

Authors:  Aysegul Saral; David A Leonard; Azer Ozad Duzgun; Aysegul Copur Cicek; Cynthia M June; Cemal Sandalli
Journal:  J Antibiot (Tokyo)       Date:  2016-05-11       Impact factor: 2.649

Review 10.  Boron chemicals in diagnosis and therapeutics.

Authors:  Bhaskar C Das; Pritam Thapa; Radha Karki; Caroline Schinke; Sasmita Das; Suman Kambhampati; Sushanta K Banerjee; Peter Van Veldhuizen; Amit Verma; Louis M Weiss; Todd Evans
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.